Home > Insider Trading > Filing (0001179110-18-013924)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1113481	Medicines Co	MDCO	Pharmaceutical Preparations (2834)	043324394

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1361754	J Alexander Denner	C/O Sarissa Capital Management Lp 660 Steamboat Road Greenwich CT 06830		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-12-13	600,000	$20.73	2,522,000	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2018-12-14	219,000	$18.97	2,741,000	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	10,429	Direct

Footnotes

Represents the weighted average purchase price of the shares purchased ranging from a low of $19.86 to a high of $21.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
All of the shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed by Sarissa Capital Management LP (such funds, the "Sarissa Funds"). Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Represents the weighted average purchase price of the shares purchased ranging from a low of $18.94 to a high of $19.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.